Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Johnson & Johnson Says US FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia

Johnson & Johnson Says US FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia

MT newswireMT newswire2026/08/25 08:09
04:09 AM EDT, 08/25/2026 (MT Newswires) -- Johnson & Johnson (JNJ) said late Monday the US Food and Drug Administration has approved Imaavy for adults and pediatric patients 12 years and older with warm autoimmune hemolytic anemia who are currently or previously treated with corticosteroids. The approval is based on the results of a phase 2/3 study in which Imaavy showed that three times as many patients achieved durable hemoglobin levels compared with placebo by 24 weeks, the company said. Johnson & Johnson said the treatment is the first FDA-approved treatment for warm autoimmune hemolytic anemia. The treatment also enabled reductions in corticosteroid use, the company said.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Korean media: Delivery times for key semiconductor equipment components have more than doubled

According to reports, there is a severe shortage of core components for semiconductor equipment in South Korea. Delivery cycles have generally doubled, and waiting times for some Japanese-made parts are as long as 40 months, with components unavailable even at a premium price. Japanese suppliers are cautious about expanding production capacity, resulting in serious delays that have impacted downstream businesses. Major construction projects like Samsung’s Pyeongtaek and SK Hynix’s Yongin face the risk of postponement, with AI chip expansion plans running into a “hard wall” in the supply chain.

华尔街见闻2026/09/18 04:16